View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 3, 2018updated 26 Nov 2018 10:13am

Bayer and Broad Institute expand heart therapy collaboration

The Broad Institute of MIT and Harvard have expanded its strategic partnership with Bayer to launch the new Precision Cardiology Laboratory (PCL), which focuses on developing new therapeutics for heart failure.

The Broad Institute of MIT and Harvard have expanded its strategic partnership with Bayer to launch the new Precision Cardiology Laboratory (PCL), which focuses on developing new therapeutics for heart failure.

To be situated at the institute, PCL will leverage new tools and approaches to gain more insights into the various causes of heart failure and treating them.

Researchers from both organisations will jointly work at the new facility, combining the institute’s basic scientific discovery innovation and clinical expertise with Bayer’s extensive drug development experience.

The laboratory initially plans to develop high-resolution, single-cell maps of cardiovascular tissues in both animal and human models.

 “Joint laboratories are a novel partnering model for industry and academia and are bringing both Bayer and Broad cardiovascular research to the next level.”

The scientists will use tissue samples from healthy people, as well as cardiovascular disease to build datasets aimed at gaining a better understanding of heart failure.

Bayer Pharmaceuticals executive committee member and R&D head Joerg Moeller said: “The Broad Institute is an important and strategic partner for Bayer, enabling us to deepen our understanding in the area of cardiovascular diseases and we are looking forward to extending our collaboration further.

“Joint laboratories are a novel partnering model for industry and academia and are bringing both Bayer and Broad cardiovascular research to the next level.”

Bayer and the Broad Institute first forged an alliance in 2013 for an oncology programme. This was later extended in 2015 to include a cardiovascular-specific project using genomics to better understand heart disease.

The new PCL will utilise non-genomic approaches to accelerate new drug targets for heart failure. As part of the now expanded collaboration, Bayer will invest $22m over the next five years.

Findings from the partnership will be openly shared via publicly available datasets and academic journals.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU